There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2
receptor blocker, shows promise for management of heart failure.